Entod Pharma gets CDSCO Panel nod to conduct Phase IV CT of Atropine Sulfate Ophthalmic Solution USP 0.05%

Published On 2025-11-19 17:12 GMT | Update On 2025-11-19 17:12 GMT

New Delhi: Approving the proposal for a Phase IV clinical study for Atropine Sulfate Ophthalmic Solution USP 0.05% w/v, the Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organization (CDSCO) has recommended that Entod Pharmaceuticals Ltd. may conduct the study as per the protocol submitted.

This came after Entod Pharmaceuticals Ltd. presented their proposal to conduct a Phase IV Clinical Study of Atropine Sulfate Ophthalmic Solution USP 0.05% w/v, submitted under Protocol ID: BCREPL-004, Version 1.0 dated 17 July 2024.

Atropine is an alkaloid derived from Atropa belladonna. It is a racemic mixture of d- and l-hyoscyamine, with only l-hyoscyamine being pharmacologically active. Clinically, atropine is available primarily as a sulfate salt and can be administered through intravenous, intramuscular, subcutaneous, intraosseous, endotracheal, and ophthalmic routes. It is widely used in ophthalmology for pupil dilation and also plays an important role in managing anticholinergic poisoning and symptomatic bradycardia. Owing to its broad therapeutic applications, atropine is listed as an essential medicine by the World Health Organization.

Also Read:0.01% atropine eye drops slows myopia progression without interfering with exotropia: JAMA

During the recent SEC meeting for ophthalmology, the committee reviewed the proposed Phase IV study design and safety assessment plan for Atropine Sulfate Ophthalmic Solution USP 0.05% w/v.

After detailed deliberation, the committee opined:

“The committee recommended approval to conduct the Phase IV Clinical Study as per the protocol presented by the firm.”

Also Read:Atropine 0.01 Percent Eye Drops Effective in Maintaining Choroidal Thickness in Myopia Treatment: MOSAIC Trial

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Susmita Roy

Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Entod Pharma gets CDSCO Panel nod to conduct Phase IV CT of Atropine Sulfate Ophthalmic Solution USP 0.05%

Similar News

High-Level Ethiopia Delegation Meets DCGI, IPC to Strengthen Pharmaceutical Ties

CDSCO Panel Asks Pure and Cure Healthcare To Revise Phase III Protocol of Tapinarof Cream 1% for Adult Psoriasis

Danish Lab Chief Held for Allegedly Supplying Fake Amoxycillin, Cefixime Under SVR Healthcare's Name

Dr Reddy's Told to Justify Patient Numbers in Vonoprazan Phase IV Trial, Revise Protocol

CDSCO Panel Asks Abbott for Proof-of-Concept Study on UDCA for Dengue Hepatic Dysfunction

CDSCO Panel Asks Zydus Lifesciences to Revise Phase I Protocol for Inactivated Chikungunya Vaccine

Health Ministry Notifies New CDSCO Drugs Inspector Recruitment Rules, 419 Posts Sanctioned for 2025